In a research report published Friday, Griffin analyst Keith Markey reiterated a Buy rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) with a price …
Wells Fargo analyst Jim Birchenough maintained an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.
Concluding another successful year, the 2016 JP Morgan Healthcare Conference has seen its share of announcements, discoveries and unveiling of things to come. Among …
J.P.
